Mucosal melanoma: Pathogenesis, clinical behavior, and management Journal Article
| Authors: | Postow, M. A.; Hamid, O.; Carvajal, R. D. |
| Article Title: | Mucosal melanoma: Pathogenesis, clinical behavior, and management |
| Abstract: | Mucosal melanoma represents a rare subtype of melanoma with distinct biological, clinical, and management considerations. Knowledge regarding optimal treatment strategies for mucosal melanoma is limited and based primarily upon small case series and single-institution, retrospective analyses. Surgery remains the standard of care for loco-regional management, but the common presence of multifocal disease and the high rate of distant recurrence should be considered before pursuing aggressive surgical interventions associated with inherent significant morbidity. The role of sentinel lymph node biopsy and lymph node dissection remains unclear. Radiotherapy has not been shown to improve overall survival but may reduce the rate of local recurrence. Significant advances in the treatment of metastatic disease have been made with novel immunotherapeutic agents, the discovery of KIT and BRAF mutations and the development of targeted agents that inhibit these oncogenic pathways. © Springer Science+Business Media, LLC 2012. |
| Keywords: | cancer surgery; gene mutation; overall survival; cisplatin; placebo; drug targeting; alpha interferon; adjuvant therapy; cancer radiotherapy; cancer staging; drug megadose; recurrence risk; lymph node metastasis; cancer incidence; lymph node dissection; sentinel lymph node biopsy; medical decision making; gene; c-kit; imatinib; stem cell factor receptor; alpha2b interferon; dacarbazine; interleukin 2; ipilimumab; cancer immunotherapy; melanoma; morbidity; dasatinib; sex ratio; vinblastine; carcinogenesis; patient care; drug research; head and neck neoplasms; cystectomy; nilotinib; risk reduction; rectal neoplasms; everolimus; b raf kinase; caucasian; mucous membrane; vulvar neoplasms; vaginal neoplasms; negro; hispanic; braf gene; rectum abdominoperineal resection; protein kinase b inhibitor; kit gene; phase 3 clinical trial (topic); disease activity; head and neck melanoma; mucosal melanoma; vemurafenib; vulvectomy; cancer prognosis; anorectal melanoma; vulvovaginal melanoma; anorectal mucosal melanoma; head and neck mucosal melanoma; vulvogainal mucosal melanoma; vulvovaginal mucosal melanoma |
| Journal Title: | Current Oncology Reports |
| Volume: | 14 |
| Issue: | 5 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2012-10-01 |
| Start Page: | 441 |
| End Page: | 448 |
| Language: | English |
| DOI: | 10.1007/s11912-012-0244-x |
| PROVIDER: | scopus |
| PUBMED: | 22661391 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 January 2013" - "CODEN: CORUA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work